Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

354

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: Pembrolizumab 25 mg/ml
DRUG: Paclitaxel injection

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]